In the INSIGHT study, the combination of tepotinib and gefitinib showed significantly a better PFS (16.6 months vs. 4.2 months) and OS (37.3 months vs. 17.9 months, respectively) than chemotherapy in patients with resistant EGFR-mutant NSCLC, especially in patients with high MET over-expression [96]. This evidence concerns the gene MET and non-small cell lung carcinoma.